Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?

about

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?

Item

http://www.wikidata.org/entity/Q41092945

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Is MPP a good prognostic facto ...... ma with EGFR exon 19 mutation?

@en

type

Item

label

Is MPP a good prognostic facto ...... ma with EGFR exon 19 mutation?

@en

prefLabel

Is MPP a good prognostic facto ...... ma with EGFR exon 19 mutation?

@en

P1476

Is MPP a good prognostic facto ...... ma with EGFR exon 19 mutation?

@en

P2093

Jing Wang

http://www.w3.org/2001/XMLSchema#string

Leina Sun

http://www.w3.org/2001/XMLSchema#string

Ping Wang

http://www.w3.org/2001/XMLSchema#string

Puchun Er

http://www.w3.org/2001/XMLSchema#string

Qi Li

http://www.w3.org/2001/XMLSchema#string

Qingna Yan

http://www.w3.org/2001/XMLSchema#string

Qingsong Pang

http://www.w3.org/2001/XMLSchema#string

Tian Zhang

http://www.w3.org/2001/XMLSchema#string

Xi Chen

http://www.w3.org/2001/XMLSchema#string

Yanjun Su

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

One hundred years of lung cancer

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.

Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.

P304

40594-40605

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.16505

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28380449

http://www.w3.org/2001/XMLSchema#string

P932

5522255

http://www.w3.org/2001/XMLSchema#string